Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and ...

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease Anemia: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering. This report covers the ...

Modus Therapeutics Holding AB has announced that the first patient has been dosed in part 2 of its ongoing phase 2a clinical study evaluating sevuparin for the treatment of chronic kidney disease (CKD ...

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025SAN FRANCISCO, (GLOBE NEWSWIRE) -- FibroGen, Inc.

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan ...

A new study published in the journal of Nature Scientific Reports showed that patients with end-stage renal disease (ESRD) ...

CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics (AKBA), Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

Dexoligo Therapeutics has presented data for their liver-targeted siRNA DXO-1801 for the potential treatment of inflammation-driven anemia, a serious complication of chronic diseases such as chronic ...

Many people take for granted the ability to travel and spend time with family and friends at their leisure — and the ability ...